Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

被引:0
|
作者
José Trigo
Mónica García-Cosío
Almudena García-Castaño
Montserrat Gomà
Ricard Mesia-Nin
Elena Ruiz-Bravo
Ainara Soria-Rivas
Paola Castillo
Irene Braña-García
Margarita Alberola-Ferranti
机构
[1] HC Marbella International Hospital,
[2] Spanish Society of Medical Oncology (SEOM),undefined
[3] Ramón y Cajal University Hospital,undefined
[4] Spanish Society of Pathological Anatomy (SEAP),undefined
[5] Marqués de Valdecilla University Hospital,undefined
[6] Spanish Society of Medical Oncology (SEOM),undefined
[7] Bellvitge University Hospital,undefined
[8] Spanish Society of Pathological Anatomy (SEAP),undefined
[9] Catalan Institute of Oncology (ICO),undefined
[10] Badalona Applied Research Group in Oncology,undefined
[11] Germans Trias i Pujol Research Institute,undefined
[12] Spanish Society of Medical Oncology (SEOM),undefined
[13] La Paz University Hospital,undefined
[14] Spanish Society of Pathological Anatomy (SEAP),undefined
[15] Ramón y Cajal University Hospital,undefined
[16] Spanish Society of Medical Oncology (SEOM),undefined
[17] Clínic de Barcelona Hospital,undefined
[18] Spanish Society of Pathological Anatomy (SEAP),undefined
[19] Vall d’Hebron University Hospital,undefined
[20] Spanish Society of Medical Oncology (SEOM),undefined
[21] Vall d’Hebron University Hospital,undefined
[22] Spanish Society of Pathological Anatomy (SEAP),undefined
来源
Clinical and Translational Oncology | 2022年 / 24卷
关键词
PD-L1; Prognosis; Individualized therapy; Response to treatment; Epstein Barr virus; Human papillomavirus;
D O I
暂无
中图分类号
学科分类号
摘要
The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.
引用
收藏
页码:1890 / 1902
页数:12
相关论文
共 50 条
  • [1] Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Trigo, Jose
    Garcia-Cosio, Monica
    Garcia-Castano, Almudena
    Goma, Montserrat
    Mesia-Nin, Ricard
    Ruiz-Bravo, Elena
    Soria-Rivas, Ainara
    Castillo, Paola
    Brana-Garcia, Irene
    Alberola-Ferranti, Margarita
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (10): : 1890 - 1902
  • [2] Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Perez, Jose Manuel Trigo
    Garcia-Cosio, Monica
    Garcia-Castano, Almudena
    Goma, Montserrat
    Mesia-Nin, Ricard
    Ruiz-Bravo, Elena
    Soria-Rivas, Ainara
    Castillo, Paola
    Brana-Garcia, Irene
    Alberola-Ferranti, Margarita
    REVISTA ESPANOLA DE PATOLOGIA, 2023, 56 (01): : 45 - 57
  • [3] Correction to: Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    José Trigo
    Mónica García-Cosío
    Almudena García-Castaño
    Montserrat Gomà
    Ricard Mesia-Nin
    Elena Ruiz-Bravo
    Ainara Soria-Rivas
    Paola Castillo
    Irene Braña-García
    Margarita Alberola-Ferranti
    Clinical and Translational Oncology, 2023, 25 : 292 - 292
  • [4] Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology (vol 24, pg 1890, 2022)
    Trigo, Jose
    Garcia-Cosio, Monica
    Garcia-Castano, Almudena
    Goma, Montserrat
    Mesia-Nin, Ricard
    Ruiz-Bravo, Elena
    Soria-Rivas, Ainara
    Castillo, Paola
    Brana-Garcia, Irene
    Alberola-Ferranti, Margarita
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (01): : 292 - 292
  • [5] Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Colomer, R.
    Aranda-Lopez, I.
    Albanell, J.
    Garcia-Caballero, T.
    Ciruelos, E.
    Lopez-Garcia, M. A.
    Cortes, J.
    Rojo, F.
    Martin, M.
    Palacios-Calvo, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (07): : 815 - 826
  • [6] Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    R. Colomer
    I. Aranda-López
    J. Albanell
    T. García-Caballero
    E. Ciruelos
    M. Á. López-García
    J. Cortés
    F. Rojo
    M. Martín
    J. Palacios-Calvo
    Clinical and Translational Oncology, 2018, 20 : 815 - 826
  • [7] Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    R. Colomer
    I. Aranda-López
    J. Albanell
    T. García-Caballero
    E. Ciruelos
    M. Á. López-García
    J. Cortés
    F. Rojo
    M. Martín
    J. Palacios-Calvo
    Clinical and Translational Oncology, 2018, 20 : 1093 - 1095
  • [8] Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    P. García-Alfonso
    R. García-Carbonero
    J. García-Foncillas
    P. Pérez-Segura
    R. Salazar
    R. Vera
    S. Ramón y Cajal
    J. Hernández-Losa
    S. Landolfi
    E. Musulén
    M. Cuatrecasas
    S. Navarro
    Clinical and Translational Oncology, 2020, 22 : 1976 - 1991
  • [9] Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Garcia-Alfonso, P.
    Garcia-Carbonero, R.
    Garcia-Foncillas, J.
    Perez-Segura, P.
    Salazar, R.
    Vera, R.
    Ramon y Cajal, S.
    Hernandez-Losa, J.
    Landolfi, S.
    Musulen, E.
    Cuatrecasas, M.
    Navarro, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (11): : 1976 - 1991
  • [10] Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    Colomer, Ramon
    Gonzalez-Farre, Blanca
    Ballesteros, Ana Isabel
    Peg, Vicente
    Bermejo, Begona
    Perez-Mies, Belen
    de la Cruz, Susana
    Rojo, Federico
    Pernas, Sonia
    Palacios, Jose
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 2935 - 2951